Bavarian Nordic to host congresswoman to discuss public-private partnerships
The meeting will be held at the corporate headquarters of Bavarian Nordic subsidiary ImmunoTherpeutics in Mountain View, California. Eshoo and Gollaher will speak with the company's management about new legislation and the benefits of public-private partnerships in cancer and biodefense research.
Eshoo is a major sponsor of the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, as well as the Recalcitrant Cancer Research Act. The RCRA was signed into law at the beginning of the year as part of the National Defense Authorization Act and PAHPA is expected to be signed into law in the next few weeks.
"We're honored that Representative Eshoo will visit Bavarian Nordic to learn more about the opportunities and challenges facing an entrepreneurial immunotherapy company," Anders Hedegaard, the president and CEO of Bavarian Nordic A/S, said. "We applaud her efforts to introduce legislation that encourages the development of early detection methods and better treatment options to improve cancer outcomes as well as medical countermeasures and are confident that such efforts will promote the continued growth of the life science industry and get innovations to patients faster."